Drug Type Small molecule drug |
Synonyms Fotagliptin, Futagliptin benzoic acid, 苯甲酸复格列汀 + [3] |
Target |
Mechanism DPP-4 inhibitors(Dipeptidyl peptidase IV inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date CN (28 Jun 2024), |
RegulationSpecial Review Project (CN), Priority Review (CN) |
Molecular FormulaC17H19FN6O |
InChIKeyIXSWMXRAIPXMRH-OAHLLOKOSA-N |
CAS Registry1312954-58-7 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diabetes Mellitus, Type 2 | CN | 28 Jun 2024 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus, Type 2 | Discovery | CN | 13 Dec 2019 |
Phase 3 | - | (uovvqvradw) = lknuzqsnka ptunmpfwlm (volsyqqyeo ) View more | Positive | 09 Oct 2023 | |||
(uovvqvradw) = tzszfmrwod ptunmpfwlm (volsyqqyeo ) View more |